AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03469700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paravertebral block
Description: Bilateral paravertebral block guided by a nerve stimulator will be performed by injecting local anesthetic mixture from levels T11 to T6. Each 20 ml of the mixture will contain: 6 ml lidocaine 2%; 6 ml lidocaine 2% with adrenaline 5 μg /ml; 5 ml bupivacaine 0.5%; 50μg fentanyl (1 ml); and 2 ml saline 0.9%
Study NCT03469700 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo PVB
Description: Placebo bilateral paravertebral block guided by a nerve stimulator will be performed by injecting normal saline from levels T11 to T6.
Study NCT03749876 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unfiltered Cigarettes
Description: Participants will be given unfiltered Pall Mall or Camel cigarettes to smoke for two weeks according to the brand they smoked prior to the start of the study. They will agree to smoke the cigarettes using a monitoring device (CReSS) that measures puffing behavior on five (5) days during each of the two weeks. They will also collect their cigarette butts on all days as a measure of smoking behaviors.
Study NCT03749876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unfiltered Cigarettes
Description: Participants will be given unfiltered Pall Mall or Camel cigarettes to smoke for two weeks according to the brand they smoked prior to the start of the study. They will agree to smoke the cigarettes using a monitoring device (CReSS) that measures puffing behavior on five (5) days during each of the two weeks. They will also collect their cigarette butts on all days as a measure of smoking behaviors.
Study NCT03749876 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Filtered Cigarettes
Description: Participants will be given filtered Pall Mall or Camel cigarettes to smoke for two weeks according to the brand they smoked prior to the start of the study. They will agree to smoke the cigarettes using a monitoring device (CReSS) that measures puffing behavior on five (5) days during each of the two weeks. They will also collect their cigarette butts on all days as a measure of smoking behaviors.
Study NCT03749876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Filtered Cigarettes
Description: Participants will be given filtered Pall Mall or Camel cigarettes to smoke for two weeks according to the brand they smoked prior to the start of the study. They will agree to smoke the cigarettes using a monitoring device (CReSS) that measures puffing behavior on five (5) days during each of the two weeks. They will also collect their cigarette butts on all days as a measure of smoking behaviors.
Study NCT03359993 — intervention group
Intervention type: PROCEDURE
Intervention: Premedication of intubation
Description: The umbilical vein is punctured to inject drugs efficiently. The access is simple, the umbilical vein is clearly visible, and a blood reflux can be found easily. We used the same equipment required for a peripheral venous injection: 24 gauge cannula, antisepsis, compress, and a syringe with the prepared anesthetic drugs. We report 5 cases of intubations in the delivery room using this method to administer the premedication.
Study NCT03845660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Alert
Description: Patients randomized to the intervention will have an alert of their prognosis based on the best available prognostic models for inpatient and 1-year mortality generated with information from their electronic health record, which will consist of a pop-up when the provider accesses a patient record to enter a progress note after the definitions for inclusions into the study have been registered.
Study NCT03308890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5mg Baraclude(entecavir)
Description: 0.5mg Baraclude (entecavir) QD for 6 months after cessation of TDF.
Study NCT03308890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5mg Baraclude(entecavir)
Description: 0.5mg Baraclude (entecavir) QD for 12 month after cessation of TDF.
Study NCT03807544 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: Transcutaneous electrical nerve stimulation
Study NCT02284776 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic education
Description: People in hydrotherapeutic cure are following a program of Therapeutic Education. This program includes dietary advice, physical activities, behavior advice in order to change the lifestyle of the obese people.
Study NCT04321746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: ketamine will be administered at a dose of 0.3 mg/kg in normal saline at 0.9% (250 mL)
Study NCT04321746 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the control group will receive only normal saline at 0.9%, with the same physical characteristics of the ketamine solution
Study NCT02932631 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: THERAPY CONTROL AND MOVEMENT OF INDUCTION
Description: Volunteers conventional physiotherapy group will stretching, strengthening and / or mobilization and functional training of the affected muscles with 3 sets of 10 repetitions for 60 minutes.~The restriction therapy group and induction motion the volunteers will wear a brace on the top healthy member to be restricted in each session during the exercises for this group for a period of 60 minutes, encouraging tasks involving activities of daily living and / or daily. In group practice mental, the volunteers listen to a CD that in the first two minutes, will promote progressive relaxation where imaginary in a calm and quiet place followed by 13 minutes of listening to the restriction therapy exercise protocol and motion induction. The association group practices and mental restriction therapy, volunteer listens to the CD for 15 minutes following the same procedures mentioned in group practice mental, followed by exercises functional activities for 45 minutes in the paretic limb.
Study NCT00751699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asacol
Description: Asacol tablets, 6 tablets per day at 7 am for 7 days
Study NCT00751699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asacol
Description: Asacol tablets, 400 mg, 2 tablets at 7 am, 3 pm, and 11 pm for 7 days
Study NCT00751699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lialda
Description: Lialda tablets 1.2 g, 2 tablets once a day at 7 am for 7 days
Study NCT01156779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR-exenatide
Description: Emulsion 0.5mg,1mg,2mg,4mg dosage (Dose-escalation) Single injection
Study NCT01156779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SR-exenatide
Description: Emulsion 0.5mg,1mg,2mg,4mg dosage (Dose-escalation) Single injection
Study NCT03003728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: ALT-803 (Interleukin-15 superagonist) 10 ug/kg via subcutaneous injection on days 1, 8, 15, and 22
Study NCT02719015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAd.CD40L
Description: Dose Escalation Phase Starting Dose: 5x10\^10 vp per tumor as an injection directly into 1-3 tumors every 3 weeks. Same tumors injected for each of the 4 injections at week 0, 3, 6 and 9. If the dose well tolerated, the rAd.CD40L escalated to 1x10\^11 vp. Subsequently enrolled patients injected at the same dose of 1x10\^11 vp. Number of injected sites/tumors increased to two sites/lesions if patients have >/=2 injectable lesions, at the same injection dose of 1x10\^10 up to three separate sites/lesions if patients have > 3 injectable lesions.~Dose Expansion Phase Starting Dose: MTD from Dose Escalation Phase.
Study NCT03444662 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: Cellulose and Sunflower oil
Study NCT03444662 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citicoline and Omega-3 supplement
Description: Citicoline and Omega-3
Study NCT03444662 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 supplement
Description: Cellulose and Omega-3
Study NCT03984864 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Description: 3-4 items from a list of 10 general exercises - intended for treatment of low back pain
Study NCT03984864 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise therapy
Description: 3-4 items from a list of 10 general exercises - intended for treatment of low back pain
Study NCT03455088 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavioral Group Therapy
Description: DBT is based on the model for the development of emotion regulation, designed for teaching how to regulate their adaptive emotions and behaviors cased by mood disorders , so it is valid for BN patient.
Study NCT01462344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADVAIR 100/50mcg
Description: fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months
Study NCT01462344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADVAIR 250/50mcg
Description: fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months
Study NCT01462344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FLOVENT 100mcg
Description: fluticasone propionate (100) twice daily (AM and PM) for 6 months
Study NCT01462344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FLOVENT 250mcg
Description: fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months
Study NCT01003249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen
Description: Subjects will be randomly assigned to placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). After the 3 week washout period, questionnaires, diary, EMG and uroflowmetry will be repeated. Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group.~Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg.
Study NCT01003249 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Baclofen
Description: Subjects will be randomly assigned to placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). After the 3 week washout period, questionnaires, diary, EMG and uroflowmetry will be repeated. Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group.~Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg.
Study NCT01003249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will then randomly be assigned in placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). After the 3 week washout period, questionnaires, diary, EMG and uroflowmetry will be repeated. Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group.~Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg.
Study NCT02719015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Dose Escalation and Expansion Phases: 2 mg/kg by vein every 3 weeks.
Study NCT03660514 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jovenes Sanos
Description: FP counselors in intervention clinics will a) provide counseling and education regarding risk of partner detection of FP methods, and women's and girls' strategies to use FP methods to minimize partner detection risk integrated into standard FP counseling, b) make brief inquiries to allow clients the opportunity to disclose experiences of RC and IPC (i.e., screening), c) provide method-specific counseling based on this information and the method chosen by the client, d) provide supported linkage of IPV survivors to local IPV support services (i.e. warm referral), and e) distribute palm-sized educational materials on RC and IPV, as well as IPV services.
Study NCT02483260 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ribavirin
Description: 1. Loading dose, 33 mg/kg (maximum dose: 2.64 g)~2. Followed in 6 hours by a dose of 16 mg/kg (maximum dose: 1.28 g) every 6 hours for the first 4 days (15 doses)~3. Followed by a dose of 8 mg/kg (maximum dose: 0.64 g) every 8 hours for the subsequent 6 days (18 doses).
Study NCT03282617 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD137L-DC-EBV-VAX
Description: Patients will receive CD137L-DC-EBV-VAX at a dose of approximately 5-50 millioncells every 2 weeks, for a total of 5-7 times.
Study NCT04529096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3016859
Description: Administered IV
Study NCT04529096 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study NCT00394992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin+capecitabine
Description: postoperatively oxaliplatin 130 mg/m2 i.v. day 1 plus capecitabine 1000 mg/m2 b.i.d. on day 1-14, q3w
Study NCT00394992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin+capecitabine+bevacizumab
Description: postoperatively oxaliplatin 130 mg/m2 i.v. day 1 plus bevacizumab 7.5 mg/kg on day 1 plus capecitabine 1000 mg/m2 b.i.d. on day 1-14, q3w
Study NCT03716804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tablet Nitrofurantoin
Description: Tablet Nitrofurantoin (100 mg), two times daily in 12 hours interval for 7 days
Study NCT03716804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tablet Ciprofloxacin/ Tablet Cefixime/ Tablet Cefuroxime
Description: Tablet Ciprofloxacin (500 mg), two times daily in 12 hours interval for 7 days or, Tablet Cefixime (200 mg), two times daily in 12 hours interval for 7 days or, Tablet Cefuroxime (250 mg), two times daily in 12 hours interval for 7 days
Study NCT03402126 — intervention group
Intervention type: OTHER
Intervention: TPD RAMWare
Description: TPD RAMWare injected into enrolled subject's Implantable cardioverter-defibrillator (ICD) device for use
Study NCT03654365 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bulk ordering and bulk messaging
Description: Patients in the intervention group had the hepatitis screening test ordered for them in bulk and then a bulk message sent to them through the personal health record describing hepatitis C and how they could be tested.
Study NCT03654365 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine alerting
Description: Passive alerting to providers (during face-to-face encounters using the electronic health record) and to patient (when they review preventative screening recommendations through their personal health record).
Study NCT03654365 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine alerting
Description: Passive alerting to providers (during face-to-face encounters using the electronic health record) and to patient (when they review preventative screening recommendations through their personal health record).
Study NCT02093650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: black cohosh extract
Description: Black cohosh extract 80 mg
Study NCT02093650 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Soy bean oil
Study NCT02275182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 0.5μg/kg Dexmedetomidine as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/min and stopped 30 minutes before the surgery over.
Study NCT02275182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.5μg/kg saline as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/min and stopped 30 minutes before the surgery over.
Study NCT04012008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive care
Description: * Regular follow-up by nephrologists every 1-3 month~* Multidisciplinary team consisting pharmacists, nurses, and dieticians
Study NCT04012008 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: * Regular follow-up by internists every 3 month~* May consult nephrologists case-by-case
Study NCT00457418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-Intron
Study NCT02261974 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Treatment Viveve
Description: Subject will receive 90 Joules/cm2 radiofrequency energy to the vaginal introitus
Study NCT02261974 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Treatment Viveve
Description: Subject will receive ≤ one (1) Joule of radiofrequency energy to the vaginal introitus
Study NCT02108366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 200mg daily
Study NCT02108366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Oseltamivir 75mg bid
Study NCT02108366 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oseltamivir
Description: Oseltamivir 75mg bid
Study NCT02108366 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule identical in appearance to celecoxib capsule, containing corn starch
Study NCT03250507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 0.25% bupivacaine for TAP block
Study NCT03250507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 0.25% bupivacaine for TAP block
Study NCT03250507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: Exparel for TAP block
Study NCT03250507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Exparel for TAP block
Study NCT03250507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Saline for TAP block that will be mixed with liposomal bupivacaine to bring the liposomal bupivacaine group to 60 mL total volume.
Study NCT04179123 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Customised PAP interfaces
Description: Customised PAP interfaces
Study NCT01366365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylnaltrexone
Study NCT01366365 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT04811911 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Narrowband ultraviolet B
Description: Patients will receive 8 sessions of NB-UVB per month for 3 successive months
Study NCT04811911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Patients will receive 25 mg/1ml of methotrexate vial per week for 3 successive months
Study NCT04295109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: the drug of intravenous patient-controlled analgesia
Description: At present, opioids are most widely used in postoperative analgesia. This study aims to use different opioid receptor agonists---fentanyl, oxycodone and butorphanol for analgesia after laparoscopic hysterectomy.Compare the recovery of gastrointestinal function after operation.
Study NCT04295109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: the drug of intravenous patient-controlled analgesia
Description: At present, opioids are most widely used in postoperative analgesia. This study aims to use different opioid receptor agonists---fentanyl, oxycodone and butorphanol for analgesia after laparoscopic hysterectomy.Compare the recovery of gastrointestinal function after operation.
Study NCT01817335 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: psychosocial assessment and care
Description: Participate in psycho-educational program
Study NCT01817335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Participate in psycho-educational program
Study NCT01817335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: communication skills training
Description: Participate in psycho-educational program
Study NCT01817335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT03225066 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Poly-L-lactic acid - Sculptra
Description: Participants using Sculptra - Poly-L-lactic acid 3 sessions in the first side and 3 sessions on the second side
Study NCT04200781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granules of Shengdi Dahuang Decoction
Description: Shengdi Dahuang Decoction contains Shengdi (rehmannia) and Dahuang ( rhubarb). Each pack of the granules of Shengdi Dahuang Decoction contains 15 grams of rehmannia and 5 grams of rhubarb.
Study NCT04200781 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo granules has the same appearence, weight, shape and color as the experimental drug.